United States Biotechnology & Medical Research

Hepion Pharmaceuticals Inc (HEPA)

Track

On April 21, 2026, multiple key executives and stakeholders at Hepion Pharmaceuticals Inc. executed significant purchase orders. Interim CEO Gary S. Stetz, Executive Chairman Vincent S. LoPriore, and other individuals acquired substantial equity positions. These transactions represent the most recent activity recorded for the firm, reflecting notable capital deployment by leadership.
Ticker: HEPA Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Hepion Pharmaceuticals Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Buy 21 Apr 2026
Value US$618,966.98 | Price 132.26 | Shares 16,980 (-14.9%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-04-27 2026-04-21 B Purchase
1.4
Purcell Michael J.
Non-Executive Director
16,980 -14.9%
132.26
US$618,967 		16,980 -14.9% 132.26 US$618,967
2026-04-27 2026-04-21 B Purchase
Stetz Gary S.

Interim CEO

Executive Director
45,083 +12.1%
118.64
US$262,670 		45,083 +12.1% 118.64 US$262,670
2026-04-27 2026-04-21 B Purchase
LoPriore Vincent S

Executive Chairman

Executive Director Large shareholder
55,890 -33.4%
202.90
US$3,766,015 		55,890 -33.4% 202.90 US$3,766,015
2026-04-27 2026-04-21 B Purchase
LoPriore Vincent S

Executive Chairman

Executive Director Large shareholder
5,000,000 +inf%
0.04
US$200,000 		5,000,000 +inf% 0.04 US$200,000
2026-04-27 2026-04-21 B Purchase
4.0
Appajosyula Sireesh
Non-Executive Director
1,250,000 +inf%
0.04
US$50,000 		1,250,000 +inf% 0.04 US$50,000
2023-11-28 2023-11-27 B Purchase
2.4
Wijngaard Peter
Non-Executive Director
2,500 +35.7%
3.05
US$7,625 		2,500 +35.7% 3.05 US$7,625
2023-11-28 2023-11-24 B Purchase
2.4
Wijngaard Peter
Non-Executive Director
2,500 +55.5%
3.09
US$7,725 		2,500 +55.5% 3.09 US$7,725
2023-09-20 2023-09-19 B Purchase
2.4
Wijngaard Peter
Non-Executive Director
1,000 +28.6%
5.64
US$5,640 		1,000 +28.6% 5.64 US$5,640
2023-09-19 2023-09-18 B Purchase
2.9
Foster Robert T

CEO and Director

Executive Director
1,600 +3.3%
5.60
US$8,960 		1,600 +3.3% 5.60 US$8,960
2023-09-20 2023-09-15 B Purchase
2.4
Wijngaard Peter
Non-Executive Director
861 +32.6%
5.37
US$4,624 		861 +32.6% 5.37 US$4,624
2023-09-20 2023-09-15 B Purchase
2.4
Wijngaard Peter
Non-Executive Director
139 +5.6%
5.45
US$758 		139 +5.6% 5.45 US$758
2023-09-20 2023-09-15 B Purchase
2.4
Wijngaard Peter
Non-Executive Director
1,000 +66.6%
5.82
US$5,820 		1,000 +66.6% 5.82 US$5,820
2023-09-18 2023-09-15 B Purchase
2.9
Foster Robert T

CEO,CSO and Director

Executive Director
1,600 +3.4%
5.40
US$8,640 		1,600 +3.4% 5.40 US$8,640
2021-02-18 2021-02-18 B Purchase
2.9
Foster Robert T

CEO and Director

Executive Director
20,000 +79.2%
2.00
US$40,000 		20,000 +79.2% 2.00 US$40,000
2021-02-18 2021-02-18 B Purchase
3.2
Cavan John T

Chief Financial Officer

Officer
10,000 +208.3%
2.00
US$20,000 		10,000 +208.3% 2.00 US$20,000
2021-02-18 2021-02-16 B Purchase
2.4
Wijngaard Peter
Non-Executive Director
10,000 +50.0%
2.20
US$22,000 		10,000 +50.0% 2.20 US$22,000
2020-12-21 2020-12-18 B Purchase
2.4
Wijngaard Peter
Non-Executive Director
20,000 +inf%
1.91
US$38,200 		20,000 +inf% 1.91 US$38,200
2020-12-08 2020-12-08 B Purchase
2.9
Foster Robert T

CEO and Director

Executive Director
25,000 +9652.5%
1.58
US$39,418 		25,000 +9652.5% 1.58 US$39,418
2020-12-02 2020-12-02 B Purchase
3.2
BRANCACCIO JOHN P
Non-Executive Director
7,000 +87500.0%
1.53
US$10,710 		7,000 +87500.0% 1.53 US$10,710
2020-12-01 2020-12-01 B Purchase
3.6
JACOB GARY S
Non-Executive Director
12,000 +20339.0%
1.66
US$19,920 		12,000 +20339.0% 1.66 US$19,920
2020-11-30 2020-11-25 B Purchase
3.2
Cavan John T

Chief Financial Officer

Officer
4,500 +1500.0%
1.62
US$7,290 		4,500 +1500.0% 1.62 US$7,290
2017-06-22 2017-06-20 B Purchase Cavan John T

CFO
20,000 +inf%
0.65
US$13,000 		20,000 +inf% 0.65 US$13,000
2016-02-18 2016-02-18 B Purchase SAPIRSTEIN JAMES

Chief Executive Officer

Executive Director
10,000 +333.3%
1.00
US$10,000 		10,000 +333.3% 1.00 US$10,000
2015-12-01 2015-11-30 B Purchase SAPIRSTEIN JAMES

Chief Executive Officer

Executive Director
500 +20.0%
2.15
US$1,075 		500 +20.0% 2.15 US$1,075
2015-11-24 2015-11-23 B Purchase SAPIRSTEIN JAMES

Chief Executive Officer

Executive Director
2,500 +inf%
1.64
US$4,100 		2,500 +inf% 1.64 US$4,100
2014-03-07 2014-03-04 B Purchase BRANCACCIO JOHN P Non-Executive Director
4,393 +218.0%
1.49
US$6,546 		4,393 +218.0% 1.49 US$6,546
Explore more

More insider trading research around Hepion Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America